RUSSO, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 338
AS - Asia 248
EU - Europa 222
AF - Africa 3
OC - Oceania 1
SA - Sud America 1
Totale 813
Nazione #
US - Stati Uniti d'America 334
CN - Cina 209
IE - Irlanda 127
FI - Finlandia 34
DE - Germania 31
SG - Singapore 19
IT - Italia 17
JP - Giappone 14
CA - Canada 4
SE - Svezia 4
AT - Austria 3
IN - India 3
ES - Italia 2
GR - Grecia 2
AU - Australia 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GB - Regno Unito 1
IR - Iran 1
MU - Mauritius 1
PH - Filippine 1
SA - Arabia Saudita 1
SL - Sierra Leone 1
Totale 813
Città #
Dublin 127
Chandler 100
Nanjing 56
Beijing 41
Helsinki 23
Ashburn 21
Nanchang 21
Boardman 17
Princeton 17
Jacksonville 16
Lawrence 16
Singapore 16
Wilmington 15
Changsha 14
Medford 14
Shenyang 14
Tokyo 14
Hebei 13
Pavia 12
Shanghai 12
Jiaxing 10
Tianjin 10
Piscataway 6
Hangzhou 5
Norwalk 4
Tamm 4
Munich 3
Toronto 3
Woodbridge 3
Athens 2
Chicago 2
Dallas 2
Falkenstein 2
Fuzhou 2
New York 2
Pune 2
Redwood City 2
Seattle 2
Taizhou 2
Vinovo 2
Zhengzhou 2
Ann Arbor 1
Brno 1
Cairo 1
Cardano 1
Cervera del Rio Alhama 1
Dearborn 1
Fairfield 1
Freetown 1
Haikou 1
Jinan 1
London 1
Los Angeles 1
Manila 1
Markham 1
Mumbai 1
Nagold 1
Ningbo 1
Orange 1
Riyadh 1
Sacramento 1
San Francisco 1
Shiraz 1
Sydney 1
Vienna 1
Totale 675
Nome #
Impact of asbestos on public health: a retrospective study on a series of subjects with occupational and non-occupational exposure to asbestos during the activity of Fibronit plant (Broni, Italy) 71
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 66
A patient with AL amyloidosis with negative free light chain results 58
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 58
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 54
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 54
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 52
Prognostication of survival and progression to dialysis in AA amyloidosis 50
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 48
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 47
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 46
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 46
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 45
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 35
The lung in amyloidosis 35
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 35
null 30
null 29
Totale 859
Categoria #
all - tutte 4.174
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.174


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202049 0 0 0 0 0 0 3 1 2 25 14 4
2020/202130 6 0 0 0 0 2 0 7 12 3 0 0
2021/202275 0 0 3 0 2 0 0 7 6 2 8 47
2022/2023301 34 33 7 15 22 25 0 13 146 0 5 1
2023/2024129 19 21 5 16 9 16 2 7 0 5 10 19
2024/202541 12 20 3 5 1 0 0 0 0 0 0 0
Totale 859